Drug Discovery World

FEBRUARY 21, 2024

The US Food and Drug Administration (FDA) has approved Eicos Sciences’ Aurlumyn (iloprost) injection, the first FDA-approved medication to treat severe frostbite. Iloprost, the active ingredient in Aurlumyn, is a vasodilator (a drug that opens blood vessels) and prevents blood from clotting.

Drugs 52

Drugs Cardiology FDA Approval Trials 52

Drug Discovery World

MARCH 15, 2023

The primary endpoint has been achieved in a Phase II trial of AP30663, a first-in-class SK ion channel inhibitor for conversion of atrial fibrillation (AF) to normal sinus rhythm. Acesion Pharma enrolled 63 patients with a current episode of AF in the trial and tested two intravenous doses of AP30663, 3 and 5mg/kg, compared to placebo.

Trials 52

Trials Cardiology Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 6, 2024

Yet, despite the overwhelming evidence linking CKD with this heightened cardiovascular risk, CKD patients are often underrepresented or outright excluded from cardiovascular clinical trials. Vice President of the Medical Department and Cardiology therapeutic lead, and Heather Lohr, Sr. Director of Clinical Trial Management.

Clinical Trials 96

Clinical Trials Clinical Trials Trials Clinical Research 96

pharmaphorum

AUGUST 30, 2022

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. In the AXIOMATIC-SSP trial, milvexian was compared to placebo in patients with prior ischaemic stroke or high-risk TIA, on top of aspirin and antiplatelet therapy.

Trials 98

Trials Cardiology Drugs 98

STAT News

AUGUST 3, 2022

Alnylam Pharmaceuticals’ treatment for an increasingly common heart disease succeeded in a closely watched clinical trial, the company said Wednesday, clearing the path to approval and affirming the promise of a drug analysts expect to reap blockbuster sales.

Trials 98

Trials Clinical Trials Clinical Trials Sales 98

Drug Discovery World

APRIL 6, 2023

A novel drug is showing promise for alleviating heart failure, a common condition associated with sleep apnoea and a reduced lifespan. The drug, known as AF-130, was tested by scientists at University of Auckland, New Zealand and the University of São Paulo, Brazil. Most patients die within five years of a heart failure diagnosis.

Drugs 52

Drugs Cardiology FDA Approval Scientist 52

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

pharmaphorum

OCTOBER 9, 2020

Shares in Amgen were down nearly 7% after close of trading yesterday after the company’s heart failure drug omecamtiv mecarbil disappointed in a large phase 3 trial. It is also hoping to steal market share from rivals with biosimilars, which are comparatively cheaper versions of biologic drugs.

Trials 52

Trials Drugs Development Marketing 52

pharmaphorum

MARCH 9, 2021

Novartis’ attempt to treat cancer with the anti-inflammatory drug canakinumab was always a long shot, but it’s nevertheless a disappointing feeling when things don’t work out. The post Novartis’ canakinumab falls short in phase 3 lung cancer trial appeared first on.

Trials 57

Trials Cardiology Branding Sales 57

Rethinking Clinical Trials

FEBRUARY 14, 2024

Both drugs have a well-established safety profile and would be a good fit for a pragmatic design. The study started in June 2016 and ended in June 2022 and ultimately found no difference between the 2 drugs in preventing major CV outcomes and non-cancer death among hypertensive VA patients. How long did the start up for the trial take?

Clinical Trials 162

Clinical Trials Clinical Trials Cardiology Trials 162

Velocity Clinical Research

NOVEMBER 21, 2023

Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. She’s been involved in several trials that have made a difference for patients, including Entresto, a drug that’s been “a big step forward for heart failure patients,” she says.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

Drug Discovery World

DECEMBER 20, 2023

The company has 155 investigators who perform trials in around 20 therapeutic areas, including infectious disease, neurology, endocrinology, oncology, cardiology, dermatology and vaccines. The post Clinical research business continues to expand in US appeared first on Drug Discovery World (DDW).

Clinical Research 52

Clinical Research Research Cardiology Dermatology 52

XTalks

JUNE 26, 2023

has announced that its new drug-coated balloon (DCB) SurVeil has been granted approval by the US Food and Drug Administration (FDA). Surmodic’s device will be going up against Medtronic’s IN.PACT Admiral balloon, which both feature balloons coated with paclitaxel (an antineoplastic drug used to prevent cell growth).

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

Delveinsight

DECEMBER 29, 2020

However, for geographies other than the US and Canada, Pfizer has received an exclusive right to develop the drug in oncology except in certain Asian countries. Audentes Therapeutics’ ASPIRO Trial Free to Proceed. The clinical hold was put after the death of three enrolled patients during the trial. mg) in the US and Canada.

Trials 52

Trials Drugs Hormones Radiology 52

The Pharma Data

AUGUST 30, 2021

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC).

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

Scienmag

NOVEMBER 16, 2020

ET, Monday, November 16, 2020, Cleveland: Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of […].

Trials 41

Trials FDA Approval Clinical Trials Clinical Trials 41

Scienmag

NOVEMBER 16, 2020

SCORED trial of patients with diabetes and chronic kidney disease is first trial of an SGLT2 inhibitor to show benefit across the full range of albuminuria; SOLOIST shows an SGLT2 inhibitor is safe to start in patients hospitalized with heart failure Boston, MA — Less than a decade ago, the Food and Drug Administration approved […].

Trials 65

Trials Drugs Clinical Trials Clinical Trials 65

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

MAY 18, 2021

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

Scienmag

OCTOBER 19, 2020

Randomized clinical trial finds no mortality risk or benefit associated with drug-coated devices in the treatment of peripheral artery disease NEW YORK – October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) (..)

Trials 51

Trials Clinical Trials Clinical Trials Drugs 51

Medical Xpress

MARCH 16, 2023

Lifestyle changes and blood pressure-reducing drugs are the mainstays of therapy for hypertension, but despite widespread availability of these approaches, many patients with hypertension are not adequately treated. Hypertension remains poorly controlled worldwide and is becoming more common.

Trials 89

Trials Drugs Cardiology 89

Drug Discovery World

MAY 3, 2023

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction. Vicore Pharma states that results from the trial are expected in Q4, 2023.

Cardiology 52

Cardiology Trials FDA Approval Drug Trials 52

Drug Discovery World

APRIL 5, 2024

The post Phase I study to evaluate treatment of worsening heart failure appeared first on Drug Discovery World (DDW). Its mechanism of action offers an opportunity for treating WHF with the goal of alleviating cardiac congestion by restoring and maintaining stable cardiovascular and renal function.

Hormones 52

Hormones Cardiology Trials Clinical Trials 52

pharmaphorum

AUGUST 13, 2020

The cholesterol-lowering drug has been classed as a breakthrough therapy for homozygous familial hypercholesterolaemia (HoFH) by the FDA, which is due to deliver a decision on the marketing application by 11 February after a truncated six-month review. Analysts put peak US sales in the region of $200 million to $400 million.

Drugs 52

Drugs Antibody Sales Cardiology 52

pharmaphorum

DECEMBER 14, 2022

An FDA advisory committee has voted against approval of Cytokinetics’ cardiac myosin inhibitor omecamtiv mecarbil for heart failure, saying the data for the drug was not strong enough. That didn’t have a direct bearing on the adcomm meeting, which focused on the GALACTIC-HF data, but reduced confidence in the drug.

Drugs 52

Drugs Trials Marketing Cardiology 52

Drug Discovery World

AUGUST 22, 2023

The drug was previously approved in China but was limited to HF patients with reduced ejection fraction (HFrEF). The approval by China’s National Medical Products Administration (NMPA) is based on positive results from the DELIVER Phase III trial. Current Cardiology Reviews. N Engl J Med. 2022; 387(12):1089-1098. Guo Y, et al.

Cardiology 52

Cardiology Trials Drugs Production 52

The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments.

Trials 52

Trials Genetics Cardiology Medicine 52

pharmaphorum

FEBRUARY 25, 2022

Eli Lilly and Boehringer Ingelheim’s blockbuster diabetes drug Jardiance (empagliflozin) has been granted approval by the US Food and Drug Administration (FDA) for a wider range of heart failure patients. . According to the FDA, heart disease impacts more than 650,000 people in the US each year. absolute risk reduction, 0.79

FDA Approval 99

FDA Approval HR Cardiology Drugs 99

XTalks

FEBRUARY 8, 2024

The top 15 diabetes drugs in 2023, according to 2022 sales data, reflect the current state of diabetes management and hint at the evolving needs and trends within this critical area of healthcare. Read on to learn more about the top 15 diabetes drugs in 2023, based on 2022 sales statistics. mL subcutaneous solution (2 mg/1.5

Sales 52

Sales Insulin FDA Approval Drugs 52

pharmaphorum

FEBRUARY 17, 2022

Bristol-Myers Squibb has new data backing up the value of mavacamten for obstructive hypertrophic cardiomyopathy (HCM), as it waits for a delayed verdict on its marketing application for the drug, acquired as part of its $13.1 billion takeover of MyoKardia in 2020.

Cardiology 57

Cardiology Trials Marketing Drugs 57

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

pharmaphorum

APRIL 12, 2021

Hope that AstraZeneca’s diabetes and heart failure drug Farxiga might treat patients hospitalised with COVID-19 have been dashed after the drug failed to make an impact in a phase 3 trial. . On the plus side, there were no safety issues in the trial.

Cardiology 81

Cardiology Antibody Trials Drugs 81

pharmaphorum

JUNE 17, 2022

The UK-based but US-listed biotech licensed rights to AZ’s orally-active neutrophil elastase inhibitor alvelestat for the rare disease alpha-1 antitrypsin deficiency (AATD) five years ago, and has since advanced the project into a phase 2 trial which is due to read out in the second half of this year.

Licensing 80

Licensing Licensing Cardiology Antibody 80

Medical Xpress

DECEMBER 5, 2022

Some immunomodulators—drugs that decrease inflammation—have been shown to reduce CV risk in the general population. People with rheumatoid arthritis are at increased risk of cardiovascular (CV) disease, with studies indicating an approximate 50 percent increase in risk of CV events such as heart attack and stroke.

Trials 66

Trials Drugs Cardiology 66

XTalks

JULY 7, 2023

a Canadian biopharmaceutical firm specializing in cardiovascular therapies, recently reported positive results from a Phase III clinical trial of its leading candidate, etripamil nasal spray, for the treatment of paroxysmal supraventricular tachycardia (PSVT). Milestone Pharmaceuticals Inc., It is then efficiently metabolized by the body.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Drugs 98

pharmaphorum

OCTOBER 24, 2022

Bristol-Myers Squibb is going after a second indication for its first-to-market cardiac myosin inhibitor Camzyos, a drug tipped to be a future blockbuster and the top prospect in the company’s growing cardiovascular pipeline. In the trial, Camzyos or placebo was added to the highest tolerated dose of standard therapy.

Drugs 40

Drugs Sales Pharmacy Trials 40

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52